Daewoong Pharma (069620) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Daewoong Pharma (069620) reported revenue of 1.57 trillion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20251.57 trillion KRW196.8 billion KRW192.9 billion KRW[source]
20241.42 trillion KRW147.9 billion KRW23.3 billion KRW[source]
20231.38 trillion KRW122.6 billion KRW120.0 billion KRW[source]
20221.28 trillion KRW95.8 billion KRW39.2 billion KRW[source]
20211.15 trillion KRW88.9 billion KRW30.3 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
20252.10 trillion KRW1.08 trillion KRW1.02 trillion KRW[source]
20241.74 trillion KRW892.6 billion KRW844.5 billion KRW[source]
20231.57 trillion KRW762.8 billion KRW803.0 billion KRW[source]
20221.37 trillion KRW714.2 billion KRW659.9 billion KRW[source]
20211.26 trillion KRW645.4 billion KRW614.3 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice